Establishment Labs (NASDAQ:ESTA) Price Target Raised to $71.00 at JPMorgan Chase & Co.

Establishment Labs (NASDAQ:ESTA) had its target price increased by equities researchers at JPMorgan Chase & Co. from $45.00 to $71.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price target suggests a potential upside of 9.38% from the stock’s current price.

Several other equities analysts have also recently weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Establishment Labs in a research note on Wednesday, October 8th. BTIG Research raised their target price on Establishment Labs from $62.00 to $70.00 and gave the company a “buy” rating in a research report on Wednesday. Needham & Company LLC raised their price target on Establishment Labs from $48.00 to $70.00 and gave the stock a “buy” rating in a research report on Thursday. Canaccord Genuity Group upped their price objective on shares of Establishment Labs from $60.00 to $72.00 and gave the company a “buy” rating in a report on Thursday. Finally, Mizuho boosted their price objective on shares of Establishment Labs from $70.00 to $85.00 and gave the stock an “outperform” rating in a research note on Thursday. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $66.71.

Establishment Labs Trading Up 7.3%

Establishment Labs stock traded up $4.40 during trading hours on Thursday, hitting $64.91. The stock had a trading volume of 1,341,311 shares, compared to its average volume of 492,831. The company has a quick ratio of 1.67, a current ratio of 2.84 and a debt-to-equity ratio of 9.71. The stock has a market cap of $1.88 billion, a price-to-earnings ratio of -21.28 and a beta of 0.98. Establishment Labs has a one year low of $26.56 and a one year high of $65.10. The business’s 50 day simple moving average is $43.18 and its 200-day simple moving average is $39.99.

Establishment Labs (NASDAQ:ESTA) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.16. The company had revenue of $53.78 million for the quarter, compared to analyst estimates of $52.28 million. Establishment Labs had a negative net margin of 49.89% and a negative return on equity of 224.34%. The firm’s revenue was up 33.8% on a year-over-year basis. During the same quarter last year, the business earned ($0.59) earnings per share. Establishment Labs has set its FY 2025 guidance at EPS. On average, equities analysts predict that Establishment Labs will post -2.41 EPS for the current fiscal year.

Institutional Trading of Establishment Labs

A number of institutional investors have recently added to or reduced their stakes in ESTA. State of Wyoming bought a new position in shares of Establishment Labs in the 3rd quarter worth $71,000. Principal Financial Group Inc. raised its holdings in Establishment Labs by 5.3% in the 3rd quarter. Principal Financial Group Inc. now owns 102,687 shares of the company’s stock worth $4,209,000 after purchasing an additional 5,134 shares during the period. Tejara Capital Ltd raised its stake in shares of Establishment Labs by 31.2% in the third quarter. Tejara Capital Ltd now owns 102,494 shares of the company’s stock valued at $4,201,000 after acquiring an additional 24,386 shares in the last quarter. Woodson Capital Management LP boosted its stake in shares of Establishment Labs by 113.3% during the 3rd quarter. Woodson Capital Management LP now owns 480,000 shares of the company’s stock worth $19,675,000 after acquiring an additional 255,000 shares in the last quarter. Finally, SG Americas Securities LLC boosted its position in Establishment Labs by 16.0% in the 3rd quarter. SG Americas Securities LLC now owns 10,110 shares of the company’s stock valued at $414,000 after buying an additional 1,398 shares during the last quarter. Hedge funds and other institutional investors own 72.91% of the company’s stock.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.